Intuitive Surgical (NASDAQ: ISRG) experienced a significant 34% decline in stock value following a slower growth forecast for da Vinci procedures. Despite this downturn, the company reported a Q2 EPS of $2.80, surpassing the consensus estimate of $2.50 for the fifth consecutive quarter. The stock currently trades at $373.71, approximately 28% below the average Wall Street price target of $477.25.
The decline in stock price is attributed to a revised full-year 2026 growth projection for da Vinci procedures, now estimated at 13.5% to 15.5%, down from the previously expected 18%. Additionally, external factors such as tariffs affecting manufacturing and a Class II recall of 11,113 da Vinci SP drapes have contributed to the negative sentiment. Despite these challenges, analysts remain optimistic, citing the company's consistent performance and the potential for the upcoming da Vinci 5 upgrade cycle.
Looking ahead, the bull case for Intuitive Surgical hinges on the anticipated success of the da Vinci 5 upgrade cycle, which could mirror the previous Xi cycle's trajectory. Analysts have rated ISRG with a mix of Strong Buy and Buy recommendations, indicating confidence in the company's long-term prospects. No further timeline was disclosed at the time of publication.
Editor's Note
Intuitive Surgical's recent stock performance highlights the volatility in the medtech sector, particularly for companies reliant on surgical robotics. The slower growth guidance raises questions about market expectations and the impact of external factors like tariffs. As the industry evolves, stakeholders should monitor how these dynamics affect investment strategies and technology adoption in robotic-assisted surgery.
Leave a comment